Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | PNMT | P11086 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2449638 | 1.00 | TAAR1 (0.46) | TAAR1MAOBPNMTIDO1AOC3 | |
| SCHEMBL5705869 | 0.84 | TAAR1 (0.61) | TAAR1AOC3CD274 | |
| Hydrochloric Acid SCHEMBL14157235 | 0.83 | TAAR1 (0.59) | TAAR1MAOBIDO1AOC3CD274 | |
| SCHEMBL6195324 | 0.81 | MPO (0.49) | TAAR1MAOBIDO1AOC3CD274 | |
| SCHEMBL15870721 | 0.79 | ACHE (0.39) | TAAR1IDO1AOC3ACHEP2RX7 | |
| SCHEMBL5854222 | 0.79 | GABRA1 (0.46) | TAAR1ACHEP2RX7 | |
| SCHEMBL214409 | 0.78 | TAAR1 (0.52) | TAAR1MAOBPNMTIDO1AOC3 | |
| SCHEMBL12065441 | 0.77 | PNMT (0.41) | TAAR1MAOBPNMTLOXL2CD274 | |
| SCHEMBL1144270 | 0.77 | ACHE (0.37) | TAAR1IDO1AOC3ACHEP2RX7 | |
| SCHEMBL11919553 | 0.77 | ACHE (0.37) | TAAR1IDO1AOC3ACHEP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170141-A1 | MRGPRX2 MODULATORS AND RELATED METHODS OF TREATMENT | INCYTE CORPORATION | 2025-05-29 | — | — | US | disclosed |
| WO-2025076455-A1 | MRGPRX2 MODULATORS AND RELATED METHODS OF TREATMENT | Escient Pharmaceuticals Inc. (US) | 2025-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170141-A1 | MRGPRX2 MODULATORS AND RELATED METHODS OF TREATMENT | MRGPRX2, MRGPRX1, MRGPRX4 | TAAR1 168/4885MAOB 3248/4885PNMT 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.